Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma

Several cancer immune intervention protocols aim at inducing T cell immunity against antigens presented by HLA‐A2, the most common human MHC class I molecule. In the context of HLA‐A*0201, we previously identified two cytotoxic T lymphocyte epitopes (E711 – 20 and E786 – 93) encoded by the human papillomavirus type 16 E7 (HPV16 E7) oncoprotein, which is a tumor‐specific antigen for cervical carcinoma. This study reports that the two HPV16 epitopes and a control hepatitis B virus epitope bind equally well to five HLA‐A2 alleles (A*0201, A*0202, A*0203, A*0204, and A*0209). These HLA‐A2 variants display comparable binding characteristics in accordance with the A2 supertype (M. F. Del Guercio et al., J. Immunol. 1995. 154: 685 – 693). Cervical carcinoma patients expressing these alleles may benefit from vaccination with the two HPV16 E7 peptides. In contrast, none of the peptides tested bound to A*0207 or A*0208, whereas heterogeneous binding was observed for A*0205 and A*0206. Therefore, the amino acid substitutions that discriminate these HLA‐A2 variants from A*0201 affect antigen presentation. Taken together, our findings have implications for application of the A2 supertype concept and for vaccination with A*0201‐binding peptides, in particular HPV16 E7 peptides.

[1]  N. Brouwenstijn,et al.  Definition of Unique and Shared T‐Cell Defined Tumor Antigens in Human Renal Cell Carcinoma , 1998, Journal of immunotherapy.

[2]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[4]  S. Burrows,et al.  Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.

[5]  J. Sidney,et al.  The HLA-A0207 Peptide Binding Repertoire is Limited to a Subset of the A0201 Repertoire , 1997 .

[6]  R W Chesnut,et al.  Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. , 1997, The Journal of clinical investigation.

[7]  R W Chesnut,et al.  Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. , 1997, Immunity.

[8]  L. Borysiewicz,et al.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. , 1997, Cancer research.

[9]  A. Rickinson,et al.  Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.

[10]  R. Offringa,et al.  Peptide-based cancer vaccines. , 1996, Current opinion in immunology.

[11]  C. Bordignon,et al.  Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. , 1996, Journal of immunology.

[12]  F. Koning,et al.  Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Stacey,et al.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer , 1996, The Lancet.

[14]  A Sette,et al.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.

[15]  F. Marincola,et al.  Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.

[16]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[17]  P. Krausa,et al.  Genetic diversity of HLA-A2: evolutionary and functional significance. , 1996, Immunology today.

[18]  A. Sette,et al.  Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. , 1996, Cancer research.

[19]  S. H. van der Burg,et al.  An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. , 1995, Human immunology.

[20]  H. Rammensee,et al.  HLA-A2 subtypes are functionally distinct in peptide binding and presentation , 1995, The Journal of experimental medicine.

[21]  H. Rammensee,et al.  Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.

[22]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[23]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[24]  M. Bunce,et al.  Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. , 1995, Tissue antigens.

[25]  G Hermanson,et al.  Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.

[26]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[27]  M. Feltkamp,et al.  Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. , 1994, Molecular immunology.

[28]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[29]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[30]  D. Wiley,et al.  The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.

[31]  J. Drijfhout,et al.  Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[32]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[33]  M. Masucci,et al.  HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. , 1993, Science.

[34]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[35]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[36]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[37]  D. Wiley,et al.  Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. , 1991, Journal of molecular biology.

[38]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[39]  P. Cresswell,et al.  Monoclonal antibody to HLA-A3. , 1982, Hybridoma.

[40]  P. Parham,et al.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. , 1981, Human immunology.

[41]  P. Parham,et al.  A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. , 1980, Human immunology.

[42]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.